Document is current
Any future updates will be listed below
-
Authors
Neogi, Tuhina https://orcid.org/0000-0002-9515-1711
Hunter, David J.
Churchill, Melvin
Shirinsky, Ivan
White, Alexander
Guermazi, Ali
Omata, Masanari
Fountaine, Robert J.
Pixton, Glenn
Viktrup, Lars
Brown, Mark T.
West, Christine R.
Verburg, Kenneth M.
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
Pfizer Inc
- License Information
-
More Information
Article History
Received: 21 April 2021
Accepted: 7 March 2022
First Online: 29 March 2022
Declarations
:
: The protocol was approved by an institutional review board or independent ethics committee at each participating investigational center. The study was conducted in compliance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice Guidelines and all participants provided written informed consent.
: Not applicable
: TN has served as a consultant to Pfizer and Eli Lilly & Company, EMD Merck Serono, Flexion, Novartis, and Regeneron. DJH has served as a consultant to Pfizer, Eli Lilly & Company, Merck Serono, and TLCBio. MC has served on advisory boards for Pfizer and Eli Lilly & Company. IS has no conflicts of interest to disclose. AW has no conflicts of interest to disclose. AG is a shareholder of BICL and LLC and has served as a consultant to MerckSerono, Pfizer, Roche, Galapagos, TissueGene, and AstraZeneca. MO has no conflicts to disclose. LV is a full-time employee of, and owns stocks in, Eli Lilly & Company. RJF, GP, MTB, CRW, and KMV are full-time employees of, and own stock and/or options in, Pfizer.
